PBYI
PUMA BIOTECHNOLOGY, INC.
PUMA BIOTECHNOLOGY, INC. (PBYI) has 13 SEC Form 4 filings (18 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Jul 9, 2026.
Insiders have net sold $1.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Alan H. Auerbach
- Employees:172
- HQ:Los Angeles, CA, US
- IPO:2012-04-24
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.1M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Market Cap
$459.9M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
AUERBACH ALAN HFirst filing | President and CEO | Sale | 44,058 | $364K | Jul 9 | SEC ↗ |
HUNT DOUGLAS MFirst filing | See Remarks | Sale | 8,460 | $70K | Jul 9 | SEC ↗ |
NOUGUES MAXIMO FFirst filing | Chief Financial Officer | Sale | 9,386 | $78K | Jul 9 | SEC ↗ |
MOYES JAY MFirst in 4 months | Director | Sale | 22,000 | $159K | Jun 15 | SEC ↗ |
Stuglik Brian MFirst filing | Director | Sale | 8,100 | $58K | Jun 15 | SEC ↗ |
Dorval AllisonFirst filing | Director | Sale | 11,610 | $84K | Jun 15 | SEC ↗ |
WILSON TROY EDWARDFirst filing | Director | Sale | 10,800 | $78K | Jun 15 | SEC ↗ |
Senderowicz AdrianFirst filing | Director | Sale | 27,000 | $194K | Jun 15 | SEC ↗ |
Related companies
PUMA BIOTECHNOLOGY, INC. is in the Healthcare sector.